---
title: "Kisqali (ribociclib), all indications: Specific populations questions"
description: "Specific populations questions on Kisqali (ribociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Kisqali be taken during pregnancy? How long is birth control needed after stopping Kisqali? Can Kisqali be taken while breastfeeding? Can Kisqali affect male fertility? 2 further questions follow. 6 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kisqali/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Kisqali (ribociclib), all indications: Specific populations questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Pregnancy and breastfeeding

<a id="kisqali-embryo-fetal-toxicity"></a>

### Can Kisqali be taken during pregnancy?

> “Based on findings from animal studies and the mechanism of action, KISQALI can cause fetal harm when administered to a 
> pregnant woman [see Clinical Pharmacology (12.1)].  
> There are no available human data informing the drug-associated risk. In animal reproduction studies, administration of 
> ribociclib to pregnant animals during organogenesis resulted in increased incidences of post implantation loss and reduced 
> fetal weights in rats and increased incidences of fetal abnormalities in rabbits at exposures 0.6 or 1.5 times the exposure in 
> humans, respectively, at the highest recommended dose of 600 mg/day based on AUC (see Data). Advise pregnant women 
> of the potential risk to a fetus.”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

> “Pregnancy Testing  
> Verify pregnancy status in females of reproductive potential prior to starting treatment with KISQALI.”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

<a id="kisqali-contraception"></a>

### How long is birth control needed after stopping Kisqali?

> “Advise females of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) 
> during treatment with KISQALI and for at least 3 weeks after the last dose.”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

<a id="kisqali-breastfeeding"></a>

### Can Kisqali be taken while breastfeeding?

> “It is not known if ribociclib is present in human milk. There are no data on the effects of ribociclib on the breastfed infant or 
> on milk production. Ribociclib and its metabolites readily passed into the milk of lactating rats. Because of the potential for 
> serious adverse reactions in breastfed infants from KISQALI, advise lactating women not to breastfeed while taking 
> KISQALI and for at least 3 weeks after the last dose.”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

> “In lactating rats administered a single dose of 50 mg/kg, exposure to ribociclib was 3.56-fold higher in milk compared to 
> maternal plasma.”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

## Specific populations

<a id="kisqali-male-fertility"></a>

### Can Kisqali affect male fertility?

> “Based on animal studies, KISQALI may impair fertility in males of reproductive potential [see Nonclinical Toxicology 
> (13.1)].”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

<a id="kisqali-children"></a>

### Is Kisqali approved for children?

> “The safety and effectiveness of KISQALI in pediatric patients have not been established.”

Source: [KISQALI: Prescribing information, page 18, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=18)

<a id="kisqali-kidney-impairment-dose"></a>

### What is the Kisqali dose for kidney (renal) impairment?

> “No dose adjustment is necessary in patients with breast cancer who have mild to moderate (30 mL/min to 
> 89 mL/min/1.73 m<sup>2</sup> ≤ estimated glomerular filtration rate (eGFR)) renal impairment. A reduced starting dose of 200 mg is 
> recommended in patients with breast cancer who have severe renal impairment [see Dosage and Administration (2.2), 
> Clinical Pharmacology (12.3)].”

Source: [KISQALI: Prescribing information, page 19, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=19)

> “In adults with severe renal impairment and end stage renal disease, ribociclib AUCinf increased 2.4-fold and 3.8-fold, and 
> Cmax increased 2.1-fold and 2.7-fold relative to the exposure in adults with normal renal function.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

## Related pages
- [Medical information: Kisqali (ribociclib): All indications](https://www.evicenter.com/medical-information/kisqali)
- [Indication](https://www.evicenter.com/medical-information/kisqali/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kisqali/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/kisqali/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kisqali/storage-and-supply)
